Literature DB >> 2123152

A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.

M Levine1, J Hirsh, J Weitz, M Cruickshank, J Neemeh, A G Turpie, M Gent.   

Abstract

Experiments in animals have demonstrated that recombinant tissue plasminogen activator (rt-PA) produces continuing thrombolysis after it is cleared from the circulation and that thrombolysis is both increased and accelerated, and bleeding is reduced when rt-PA is administered over a short period. In previous studies in patients with thrombotic disease, rt-PA has been shown to be an effective thrombolytic agent when administered by continuous infusion over a period between 90 minutes and 8 hours. To determine whether a short course regimen of rt-PA can achieve thrombolysis, a double-blind randomized trial has been conducted in which patients with objectively established acute symptomatic pulmonary embolism who were receiving heparin were allocated to either a 2-minute infusion of rt-PA at a dose of 0.6 mg/kg (33 patients) or saline placebo (25 patients). Perfusion lung scanning was used to assess the change in pulmonary perfusion at 24 hours and seven days post-study drug administration. Thirty-four percent of the rt-PA patients had a greater than 50 percent resolution in the perfusion defect at 24 hours compared to 12 percent of placebo patients (p = 0.026). At 24 hours, the mean relative improvement in the perfusion defect was 37.0 percent in rt-PA treated patients compared to 18.8 percent in the placebo group (p = 0.017). By day 7, no difference in lung scan resolution was detected between the groups. There were no major bleeds in either group nor were there any differences in transfusion requirements between groups. Minor bleeding occurred in 15 of the rt-PA patients mainly at angiogram-catheter insertion and venipuncture sites. These results suggest that a bolus regimen of rt-PA produces accelerated thrombolysis and provides an alternative and convenient approach to thrombolytic therapy in patients with pulmonary embolism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2123152     DOI: 10.1378/chest.98.6.1473

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  42 in total

1.  Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.

Authors:  J F Liang; Y T Li; M E Connell; V C Yang
Journal:  AAPS PharmSci       Date:  2000

Review 2.  When should we thrombolyse patients with pulmonary embolism? A systematic review of the literature.

Authors:  T Harris; S Meek
Journal:  Emerg Med J       Date:  2005-11       Impact factor: 2.740

3.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  "Empirical" thrombolysis in catastrophic pulmonary embolism.

Authors:  T Kehoe; D DaCruz
Journal:  J Accid Emerg Med       Date:  1999-01

Review 5.  The role of thrombolytic therapy in pulmonary embolism.

Authors:  Tzu-Fei Wang; Alessandro Squizzato; Francesco Dentali; Walter Ageno
Journal:  Blood       Date:  2015-01-28       Impact factor: 22.113

6.  [Acute pulmonary embolism: still a diagnostic and therapeutic challenge?]

Authors:  R Felgendreher; D Härtel; J Brockmeier; K Bramlage; T Aschenbrenner; J Götz; P Bramlage; U Tebbe
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-11-02       Impact factor: 0.840

7.  Systemic Full Dose, Half Dose, and Catheter Directed Thrombolysis for Pulmonary Embolism. When to Use and How to Choose?

Authors:  Mohsen Sharifi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-05

8.  Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis.

Authors:  Ariel Izcovich; Juan M Criniti; Federico Popoff; Liming Lu; Jiaming Wu; Walter Ageno; Daniel M Witt; Michael R Jaff; Sam Schulman; Veena Manja; Peter Verhamme; Gabriel Rada; Yuqing Zhang; Robby Nieuwlaat; Wojtek Wiercioch; Holger J Schünemann; Ignacio Neumann
Journal:  Blood Adv       Date:  2020-04-14

Review 9.  [Errors and risks in perioperative thrombolysis therapy].

Authors:  F Spöhr; B W Böttiger; A Walther
Journal:  Anaesthesist       Date:  2005-05       Impact factor: 1.041

Review 10.  Diagnosis of pulmonary embolism.

Authors:  Clive Kearon
Journal:  CMAJ       Date:  2003-01-21       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.